These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34519101)

  • 1. The RNA binding protein human antigen R is a gatekeeper of liver homeostasis.
    Subramanian P; Gargani S; Palladini A; Chatzimike M; Grzybek M; Peitzsch M; Papanastasiou AD; Pyrina I; Ntafis V; Gercken B; Lesche M; Petzold A; Sinha A; Nati M; Thangapandi VR; Kourtzelis I; Andreadou M; Witt A; Dahl A; Burkhardt R; Haase R; Domingues AMJ; Henry I; Zamboni N; Mirtschink P; Chung KJ; Hampe J; Coskun Ü; Kontoyiannis DL; Chavakis T
    Hepatology; 2022 Apr; 75(4):881-897. PubMed ID: 34519101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic HuR protects against the pathogenesis of non-alcoholic fatty liver disease by targeting PTEN.
    Tian M; Wang J; Liu S; Li X; Li J; Yang J; Zhang C; Zhang W
    Cell Death Dis; 2021 Mar; 12(3):236. PubMed ID: 33664225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.
    Newberry EP; Hall Z; Xie Y; Molitor EA; Bayguinov PO; Strout GW; Fitzpatrick JAJ; Brunt EM; Griffin JL; Davidson NO
    Hepatology; 2021 Sep; 74(3):1203-1219. PubMed ID: 33638902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression.
    Wang Y; Tai YL; Way G; Zeng J; Zhao D; Su L; Jiang X; Jackson KG; Wang X; Gurley EC; Liu J; Liu J; Chen W; Wang XY; Sanyal AJ; Hylemon PB; Zhou H
    Cell Biosci; 2022 Oct; 12(1):172. PubMed ID: 36224648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CerS5 deficiency promotes liver fibrosis development in non-alcoholic fatty liver disease.
    Chen J; Hao Y; Xu P; Bian D; Han L; Wu X; Zhuang Z; Wang J; Luo Y
    Biochem Biophys Res Commun; 2023 Jul; 667():120-126. PubMed ID: 37216827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic HuR modulates lipid homeostasis in response to high-fat diet.
    Zhang Z; Zong C; Jiang M; Hu H; Cheng X; Ni J; Yi X; Jiang B; Tian F; Chang MW; Su W; Zhu L; Li J; Xiang X; Miao C; Gorospe M; de Cabo R; Dou Y; Ju Z; Yang J; Jiang C; Yang Z; Wang W
    Nat Commun; 2020 Jun; 11(1):3067. PubMed ID: 32546794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key features of the environment promoting liver cancer in the absence of cirrhosis.
    Zaki MYW; Mahdi AK; Patman GL; Whitehead A; Maurício JP; McCain MV; Televantou D; Abou-Beih S; Ramon-Gil E; Watson R; Cox C; Leslie J; Wilson C; Govaere O; Lunec J; Mann DA; Nakjang S; Oakley F; Shukla R; Anstee QM; Tiniakos D; Reeves HL
    Sci Rep; 2021 Aug; 11(1):16727. PubMed ID: 34408183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer.
    Zhu H; Berkova Z; Mathur R; Sehgal L; Khashab T; Tao RH; Ao X; Feng L; Sabichi AL; Blechacz B; Rashid A; Samaniego F
    Mol Cancer Res; 2015 May; 13(5):809-18. PubMed ID: 25678597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis.
    Mohammed S; Thadathil N; Ohene-Marfo P; Tran AL; Van Der Veldt M; Georgescu C; Oh S; Nicklas EH; Wang D; Haritha NH; Luo W; Janknecht R; Miller BF; Wren JD; Freeman WM; Deepa SS
    Mol Cancer Res; 2023 Sep; 21(9):933-946. PubMed ID: 37204757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of hepatic Mboat7 leads to liver fibrosis.
    Thangapandi VR; Knittelfelder O; Brosch M; Patsenker E; Vvedenskaya O; Buch S; Hinz S; Hendricks A; Nati M; Herrmann A; Rekhade DR; Berg T; Matz-Soja M; Huse K; Klipp E; Pauling JK; Wodke JA; Miranda Ackerman J; Bonin MV; Aigner E; Datz C; von Schönfels W; Nehring S; Zeissig S; Röcken C; Dahl A; Chavakis T; Stickel F; Shevchenko A; Schafmayer C; Hampe J; Subramanian P
    Gut; 2021 May; 70(5):940-950. PubMed ID: 32591434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic inactivation of the LIGHT (TNFSF14) cytokine in mice restores glucose homeostasis and diminishes hepatic steatosis.
    Herrero-Cervera A; Vinué Á; Burks DJ; González-Navarro H
    Diabetologia; 2019 Nov; 62(11):2143-2157. PubMed ID: 31388695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
    Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S
    Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
    Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
    Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
    Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
    Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis.
    Kumar S; Verma AK; Rani R; Sharma A; Wang J; Shah SA; Behari J; Salazar Gonzalez R; Kohli R; Gandhi CR
    Hepatology; 2020 Nov; 72(5):1586-1604. PubMed ID: 32031683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deranged hepatocyte intracellular Ca
    Ali ES; Rychkov GY; Barritt GJ
    Cell Calcium; 2019 Sep; 82():102057. PubMed ID: 31401389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.